Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
作者： Luis Fernández-Salazar , Fernando Muñoz , Jesús Barrio , Concepción Muñoz , Ramón Pajares
DOI: 10.3109/00365521.2015.1070900
关键词:
摘要: AbstractObjective. To describe clinical practice with infliximab (IFX) in ulcerative colitis (UC); identification of predictive factors for IFX treatment discontinuation due to insufficient response and colectomy. Material methods. Retrospective, multicentric observational study including every UC IFX-treated patient 10 Spanish hospitals. Variables analyzed: epidemiological data; variables poor prognosis; prior treatments; characteristics the treatment; time from diagnosis induction IFX; colectomy or until data collection. Predictive protective lack were analyzed binary logistic regression Cox analysis. Results. Follow-up collection colectomy: 36.7 ± 25.7 months. Prior immunomodulator medications (IMM): 79%; + immunosuppressant therapy: 77%; IFX: 26%, 16%. Independ...
sci-hub.se 参考文章(32)
Jerome Filippi, Patrick B. Allen, Xavier Hebuterne, Laurent Peyrin-Biroulet, Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. Current Drug Targets. ,vol. 12, pp. 1440- 1447 ,(2011) , 10.2174/138945011796818153
Yoko Yokoyama, Katsuyoshi Matsuoka, Taku Kobayashi, Koji Sawada, Tateshi Fujiyoshi, Takafumi Ando, Yoshifumi Ohnishi, Tetsuya Ishida, Masashi Oka, Masahiro Yamada, Takashi Nakamura, Tomoko Ino, Toyoko Numata, Hirofumi Aoki, Jun-ichi Sakou, Masahiro Kusada, Tomoki Maekawa, Toshifumi Hibi, A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: Treatment outcomes of 847 patients in clinical practice Journal of Crohn's and Colitis. ,vol. 8, pp. 981- 991 ,(2014) , 10.1016/J.CROHNS.2014.01.027
Mirthe Emilie van der Valk, Marie-Josée J Mangen, Max Leenders, Gerard Dijkstra, Ad A van Bodegraven, Herma H Fidder, Dirk J de Jong, Marieke Pierik, C Janneke van der Woude, Mariëlle JL Romberg-Camps, Cees HM Clemens, Jeroen M Jansen, Nofel Mahmmod, Paul C van de Meeberg, Andrea E van der Meulen-de, Cyriel Y Ponsioen, Clemens JM Bolwerk, J Reinoud Vermeijden, Peter D Siersema, Martijn GH van Oijen, Bas Oldenburg, COIN Study Group, Dutch Initiative on Crohn and Colitis, Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study Gut. ,vol. 63, pp. 72- 79 ,(2014) , 10.1136/GUTJNL-2012-303376
Walter Reinisch, William J. Sandborn, Paul Rutgeerts, Brian G. Feagan, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Marion Blank, Yinghua Lang, Jewel Johanns, Jean Frédéric Colombel, Daniel Present, Bruce E. Sands, Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension Studies Inflammatory Bowel Diseases. ,vol. 18, pp. 201- 211 ,(2012) , 10.1002/IBD.21697
Paul Rutgeerts, William J. Sandborn, Brian G. Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Suzanne Travers, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Daniel Present, Bruce E. Sands, Jean Frédéric Colombel, Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis The New England Journal of Medicine. ,vol. 353, pp. 2462- 2476 ,(2005) , 10.1056/NEJMOA050516
Alessandro Armuzzi, Daniela Pugliese, Silvio Danese, Gianluca Rizzo, Carla Felice, Manuela Marzo, Gialuca Andrisani, Gionata Fiorino, Orsola Sociale, Alfredo Papa, Italo De Vitis, Gian Lodovico Rapaccini, Luisa Guidi, Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflammatory Bowel Diseases. ,vol. 19, pp. 1065- 1072 ,(2013) , 10.1097/MIB.0B013E3182802909
I. Blumenstein, E. Herrmann, N. Filmann, C. Zosel, W. Tacke, H. Bock, A. Dignaß, F. Hartmann, S. Zeuzem, J. Stein, O. Schröder, Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: A subgroup analysis of a large multi-centre, prospective, internet-based study Journal of Crohn's and Colitis. ,vol. 5, pp. 203- 210 ,(2011) , 10.1016/J.CROHNS.2010.12.012
M Chaparro, P Burgueño, E Iglesias, J Panés, F Muñoz, G Bastida, L Castro, C Jiménez, JL Mendoza, M Barreiro‐de Acosta, S Gomez Senent, F Gomollón, X Calvet, E García‐Planella, M Gómez, V Hernández, J Hinojosa, M Mañosa, O Perez Nyssen, JP Gisbert, None, Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study Alimentary Pharmacology & Therapeutics. ,vol. 35, pp. 275- 283 ,(2012) , 10.1111/J.1365-2036.2011.04934.X
Kang-Moon Lee, Yoon Tae Jeen, Ju Yeon Cho, Chang Kyun Lee, Ja-Seol Koo, Dong Il Park, Jong Pil Im, Soo Jung Park, You Sun Kim, Tae Oh Kim, Suck-Ho Lee, Byung Ik Jang, Ji Won Kim, Young Sook Park, Eun-Soo Kim, Chang Hwan Choi, Hyo Jong Kim, , Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study Journal of Gastroenterology and Hepatology. ,vol. 28, pp. 1829- 1833 ,(2013) , 10.1111/JGH.12324
Shuji Yamamoto, Hiroshi Nakase, Minoru Matsuura, Yusuke Honzawa, Satohiro Masuda, Ken-ichi Inui, Tsutomu Chiba, Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. Journal of Gastroenterology and Hepatology. ,vol. 25, pp. 886- 891 ,(2010) , 10.1111/J.1440-1746.2009.06206.X